Cynata Therapeutics Limited (CYYNF) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Corticosteroids, Cyp-001: Cymerus Induced Pluripotent Stem Cell (Ipsc)-Derived Mesenchymal Stem Cells (Mscs) | Graft Versus Host Disease, Acute | Phase II | Recruiting | A Study of CYP-001 in Combination with Corticosteroids in Adults with High-risk AGvHD | Nov 29, 2022 | ― |
| Cyp-006Tk | Diabetic Foot Ulcer, Cutaneous Ulcer | Phase I | Completed | Safety, Tolerability and Efficacy of CYP-006TK in Adults with Diabetic Foot Ulcers | Oct 18, 2021 | ― |
| Cyp-001 | COVID19, Acute Respiratory Distress Syndrome | Phase I | Completed | The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause | Aug 25, 2020 | ― |
| Mesenchymoangioblast-Derived Mesenchymal Stem Cells | Graft Vs Host Disease | Phase I | Completed | A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease | Oct 03, 2016 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Corticosteroids, Cyp-001: Cymerus Induced Pluripotent Stem Cell (Ipsc)-Derived Mesenchymal Stem Cells (Mscs) | Phase II | Graft Versus Host Disease, Acute | Recruiting | A Study of CYP-001 in Combination with Corticosteroids in Adults with High-risk AGvHD | Nov 29, 2022 | ― |
| Cyp-006Tk | Phase I | Diabetic Foot Ulcer, Cutaneous Ulcer | Completed | Safety, Tolerability and Efficacy of CYP-006TK in Adults with Diabetic Foot Ulcers | Oct 18, 2021 | ― |
| Cyp-001 | Phase I | COVID19, Acute Respiratory Distress Syndrome | Completed | The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause | Aug 25, 2020 | ― |
| Mesenchymoangioblast-Derived Mesenchymal Stem Cells | Phase I | Graft Vs Host Disease | Completed | A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease | Oct 03, 2016 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Cynata Therapeutics Limited (CYYNF) have in its pipeline
Cynata Therapeutics Limited CYYNF is currently developing the following drugs: Corticosteroids, Cyp-001: Cymerus Induced Pluripotent Stem Cell (Ipsc)-Derived Mesenchymal Stem Cells (Mscs), Cyp-006Tk, Cyp-001, Mesenchymoangioblast-Derived Mesenchymal Stem Cells. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
